These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9794841)

  • 1. The use of antibodies against the IL-2 receptor in transplantation.
    Waldmann TA; O'Shea J
    Curr Opin Immunol; 1998 Oct; 10(5):507-12. PubMed ID: 9794841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
    Pascual J; Marcén R; Ortuño J
    Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR; Faulds D
    Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F
    Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
    [No Abstract]   [Full Text] [Related]  

  • 7. Daclizumab.
    Mottershead M; Neuberger J
    Expert Opin Biol Ther; 2007 Oct; 7(10):1583-96. PubMed ID: 17916050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive [correction of immunosupressive] agents and their actions.
    First MR
    Transplant Proc; 2002 Aug; 34(5):1369-71. PubMed ID: 12176401
    [No Abstract]   [Full Text] [Related]  

  • 9. The interleukin-2 inhibitors and their role in low-toxicity regimens.
    Nashan B
    Transplant Proc; 1999 Dec; 31(8A):23S-26S. PubMed ID: 10616557
    [No Abstract]   [Full Text] [Related]  

  • 10. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B; Light S; Hardie IR; Lin A; Johnson JR
    Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group.
    Hengster P; Pescovitz MD; Hyatt D; Margreiter R
    Transplantation; 1999 Jul; 68(2):310-3. PubMed ID: 10440409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclizumab: a review of its use in the management of organ transplantation.
    Carswell CI; Plosker GL; Wagstaff AJ
    BioDrugs; 2001; 15(11):745-73. PubMed ID: 11707149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody.
    Garrity ER; Villanueva J; Bhorade SM; Husain AN; Vigneswaran WT
    Transplantation; 2001 Mar; 71(6):773-7. PubMed ID: 11330541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
    Waldmann TA
    J Clin Immunol; 2007 Jan; 27(1):1-18. PubMed ID: 17216565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
    N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects].
    ter Meulen CG; Hilbrands LB; van Riemsdijk-van Overbeeke IC; Hené RJ; Christiaans MH; Hoitsma AJ
    Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2396-400. PubMed ID: 11145094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.
    Beniaminovitz A; Itescu S; Lietz K; Donovan M; Burke EM; Groff BD; Edwards N; Mancini DM
    N Engl J Med; 2000 Mar; 342(9):613-9. PubMed ID: 10699160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical advances in therapies targeting the interleukin-2 receptor.
    Church AC
    QJM; 2003 Feb; 96(2):91-102. PubMed ID: 12589007
    [No Abstract]   [Full Text] [Related]  

  • 19. [Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].
    Madsen M; Svendsen UG
    Ugeskr Laeger; 2000 Oct; 162(42):5648-52. PubMed ID: 11059309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
    Van Gelder T; Warlé M; Ter Meulen RG
    Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.